Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
Abstract The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical, laboratory and echocardiographic parameters and outcomes in a real-world population with heart failure with reduced ejection fraction (HFrEF). This was a prospective observational study enrolling pa...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c4eb79d743ba47cb96ae9674c35a7a14 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c4eb79d743ba47cb96ae9674c35a7a14 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c4eb79d743ba47cb96ae9674c35a7a142021-12-02T18:27:50ZClinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction10.1038/s41598-020-63801-22045-2322https://doaj.org/article/c4eb79d743ba47cb96ae9674c35a7a142020-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-63801-2https://doaj.org/toc/2045-2322Abstract The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical, laboratory and echocardiographic parameters and outcomes in a real-world population with heart failure with reduced ejection fraction (HFrEF). This was a prospective observational study enrolling patients with HFrEF undergoing treatment with S/V. The primary outcome was the composite of cardiac death and HF rehospitalization at 12 months follow-up; secondary outcomes were all-cause death, cardiac death and the occurrence of rehospitalization for worsening HF. The clinical outcome was compared with a retrospective cohort of 90 HFrEF patients treated with standard medical therapy. The study included 90 patients (66.1 ± 11.7 years) treated with S/V. The adjusted regression analysis showed a significantly lower risk for the primary outcome (HR:0.31; 95%CI, 0.11–0.83; p = 0.019) and for HF rehospitalization (HR:0.27; 95%CI, 0.08–0.94; p = 0.039) in S/V patients as compared to the control group. A significant improvement in NYHA class, left ventricular ejection fraction, left ventricular end systolic volume and systolic pulmonary arterial pressure was observed up to 6 months. S/V did not affect negatively renal function and was associated with a significantly lower dose of furosemide dose prescribed at 6- and 12-month follow-up. In this study, S/V reduced the risk of HF rehospitalization and cardiac death at 1 year in patients with HFrEF. S/V improved NYHA class, echocardiographic parameters and need of furosemide, and preserved renal function.Maria Vincenza PolitoAngelo SilverioAntonella RispoliGennaro VitulanoFederica D’ AuriaElena De AngelisFrancesco LoriaAlberto GigantinoDomenico BonadiesRodolfo CitroAlbino CarrizzoGennaro GalassoGuido IaccarinoCarmine VecchioneMichele CiccarelliNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-10 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Maria Vincenza Polito Angelo Silverio Antonella Rispoli Gennaro Vitulano Federica D’ Auria Elena De Angelis Francesco Loria Alberto Gigantino Domenico Bonadies Rodolfo Citro Albino Carrizzo Gennaro Galasso Guido Iaccarino Carmine Vecchione Michele Ciccarelli Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction |
| description |
Abstract The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical, laboratory and echocardiographic parameters and outcomes in a real-world population with heart failure with reduced ejection fraction (HFrEF). This was a prospective observational study enrolling patients with HFrEF undergoing treatment with S/V. The primary outcome was the composite of cardiac death and HF rehospitalization at 12 months follow-up; secondary outcomes were all-cause death, cardiac death and the occurrence of rehospitalization for worsening HF. The clinical outcome was compared with a retrospective cohort of 90 HFrEF patients treated with standard medical therapy. The study included 90 patients (66.1 ± 11.7 years) treated with S/V. The adjusted regression analysis showed a significantly lower risk for the primary outcome (HR:0.31; 95%CI, 0.11–0.83; p = 0.019) and for HF rehospitalization (HR:0.27; 95%CI, 0.08–0.94; p = 0.039) in S/V patients as compared to the control group. A significant improvement in NYHA class, left ventricular ejection fraction, left ventricular end systolic volume and systolic pulmonary arterial pressure was observed up to 6 months. S/V did not affect negatively renal function and was associated with a significantly lower dose of furosemide dose prescribed at 6- and 12-month follow-up. In this study, S/V reduced the risk of HF rehospitalization and cardiac death at 1 year in patients with HFrEF. S/V improved NYHA class, echocardiographic parameters and need of furosemide, and preserved renal function. |
| format |
article |
| author |
Maria Vincenza Polito Angelo Silverio Antonella Rispoli Gennaro Vitulano Federica D’ Auria Elena De Angelis Francesco Loria Alberto Gigantino Domenico Bonadies Rodolfo Citro Albino Carrizzo Gennaro Galasso Guido Iaccarino Carmine Vecchione Michele Ciccarelli |
| author_facet |
Maria Vincenza Polito Angelo Silverio Antonella Rispoli Gennaro Vitulano Federica D’ Auria Elena De Angelis Francesco Loria Alberto Gigantino Domenico Bonadies Rodolfo Citro Albino Carrizzo Gennaro Galasso Guido Iaccarino Carmine Vecchione Michele Ciccarelli |
| author_sort |
Maria Vincenza Polito |
| title |
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction |
| title_short |
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction |
| title_full |
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction |
| title_fullStr |
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction |
| title_full_unstemmed |
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction |
| title_sort |
clinical and echocardiographic benefit of sacubitril/valsartan in a real-world population with hf with reduced ejection fraction |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/c4eb79d743ba47cb96ae9674c35a7a14 |
| work_keys_str_mv |
AT mariavincenzapolito clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT angelosilverio clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT antonellarispoli clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT gennarovitulano clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT federicadauria clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT elenadeangelis clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT francescoloria clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT albertogigantino clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT domenicobonadies clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT rodolfocitro clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT albinocarrizzo clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT gennarogalasso clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT guidoiaccarino clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT carminevecchione clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction AT micheleciccarelli clinicalandechocardiographicbenefitofsacubitrilvalsartaninarealworldpopulationwithhfwithreducedejectionfraction |
| _version_ |
1718378005981560832 |